Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.09 USD | -0.91% |
|
+0.69% | -11.87% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.87% | 477M | |
+18.22% | 125B | |
+13.25% | 108B | |
-7.23% | 24.21B | |
+2.10% | 22.78B | |
-10.77% | 17.96B | |
-41.74% | 16.43B | |
-12.81% | 16.37B | |
+1.11% | 13.58B | |
+27.02% | 11.66B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug